TREACE MEDICAL CONCEPTS INC
For the period ended Dec 31, 2023. Filed Feb 27, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 27, 2024
TMCI$4.78+18.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Stockholders' Equity
(in thousands, except share amounts)
| Accumulated | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Convertible · Additional · Other · Total | |||||||||||||||||||
| Preferred Stock · Common Stock · Paid-In · Accumulated · Comprehensive · Treasury · Stockholders’ | |||||||||||||||||||
| Shares · Amount · Shares · Amount · Capital · Deficit · Loss · Stock · Equity | |||||||||||||||||||
| Balances at January 1, 2021 | 6,687,475 | $7,935 | 37,366,865 | $28 | $14,166 | $(21,353) | $— | $— | $776 | ||||||||||
| Issuance of common stock upon exercise of stock options | — | — | 2,368,705 | 2 | 1,828 | — | — | — | 1,830 | ||||||||||
| Issuance of restricted stock awards | — | — | 24,895 | — | — | — | — | — | — | ||||||||||
| Share-based compensation expense | — | — | — | — | 3,409 | — | — | — | 3,409 | ||||||||||
| Issuance of common stock from public offering, net of issuance costs and underwriting discount of $10.6 million | — | — | 6,953,125 | 7 | 107,603 | — | — | — | 107,610 | ||||||||||
| Issuance of common stock upon net exercise of warrants | — | — | 621,570 | 1 | (1) | — | — | — | — | ||||||||||
| Conversion of convertible preferred stock and accrued dividends on convertible preferred stock into common stock | (6,687,475) | (7,935) | 6,845,922 | 7 | 7,928 | — | — | — | — | ||||||||||
| Net loss | — | — | — | — | — | (20,552) | (20,552) | ||||||||||||
| Balances at December 31, 2021 | — | $— | 54,181,082 | $45 | $134,933 | $(41,905) | $— | $— | $93,073 | ||||||||||
| Issuance of common stock upon exercise of stock options | — | — | 1,444,626 | 10 | 2,177 | — | — | — | 2,187 | ||||||||||
| Issuance of common stock for vesting of restricted stock units | — | — | 2,500 | — | — | — | — | — | — | ||||||||||
| Share-based compensation expense | — | — | — | — | 8,111 | — | — | — | 8,111 | ||||||||||
| Net loss | — | — | — | — | — | (42,815) | — | — | (42,815) | ||||||||||
| Unrealized loss on available-for-sale marketable securities | — | — | — | — | — | — | (27) | — | (27) | ||||||||||
| Balances at December 31, 2022 | — | $— | 55,628,208 | $55 | $145,221 | $(84,720) | $(27) | $— | $60,529 | ||||||||||
| Issuance of common stock upon exercise of stock options | — | — | 495,337 | 1 | 1,868 | — | — | — | 1,869 | ||||||||||
| Issuance of common stock for vesting of restricted stock units | — | — | 149,919 | — | — | — | — | — | — | ||||||||||
| Share-based compensation expense | — | — | — | — | 17,363 | — | — | — | 17,363 | ||||||||||
| Issuance of common stock from public offering, net of issuance costs and underwriting discount of $7.5 million | 5,476,190 | 6 | 107,521 | — | — | — | 107,527 | ||||||||||||
| Net loss | — | — | — | — | — | (49,527) | — | — | (49,527) | ||||||||||
| Unrealized loss on available-for-sale marketable securities | — | — | — | — | — | 190 | — | 190 | |||||||||||
| Shares directly withheld from employees for tax payment | — | — | — | — | — | (13) | (13) | ||||||||||||
| Balances at December 31, 2023 | — | $— | 61,749,654 | $62 | $271,973 | $(134,247) | $163 | $(13) | $137,938 | ||||||||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.